Evotec: Recovery Seems To Be Beginning
Source: SeekingAlpha
2025-07-23 05:43:11 ET
I've been covering Evotec ( EVO ) using my small position in this German drug discovery company for exposure to what I view as a volatile but potentially attractive market for returns. The returns so far have been a mixed bag. In my last article, I was positive - you can find that article here . However, the company's returns since that time have been negative compared to the SPY. If you're to look at the article before that one in Fall of 2024, however, that return is positive, and even market-beating, at about 13%. ...
Read the full article on Seeking Alpha
For further details see:
Evotec: Recovery Seems To Be Beginning
Evotec SE
NASDAQ: EVO
EVO Trading
-3.7% G/L:
$2.345 Last:
87,481 Volume:
$2.35 Open:
EVO Latest News
January 08, 2026 01:50:00 am
Just - Evotec Biologics Receives Grant for AI-Driven Optimization of Monoclonal Antibody Developability for Affordable Access
January 02, 2026 12:30:00 am
Evotec Appoints Dr. Sarah Fakih as EVP, Head of Global Communications and Investor Relations
December 08, 2025 01:20:00 am
Evotec Closes Sale of Just - Evotec Biologics' Toulouse Site to Sandoz
December 04, 2025 02:50:00 am
Evotec-Partner Bayer Starts Phase 2 Study for Treatment of Patients with Alport Syndrome
EVO Stock Data
$320,181,806
73,171,742
N/A
9
N/A
Biotechnology & Life Sciences
Healthcare
DE
Hamburg
